Novavax Recognized by Washington Post as Top Workplace

GAITHERSBURG, Md., June 19, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that, for the second consecutive year, it has been recognized as a Top Workplace for 2015.

“This recognition is a testament to the passion and dedication of our 350 SuperNovas,” said Stanley C. Erck, President and CEO. “Our employees exemplify the excellence and commitment necessary to make an impact on global health. I come to work every day excited to work with each and every one of them.”

The Washington Post Top Workplaces are determined solely on employee feedback via an employee survey conducted by WorkplaceDynamics, LLP, a leading research firm on organizational health and employee engagement.

Jill Hoyt, Vice President, Human Resources, said, “It is an honor to receive this recognition for the second year in a row. This award underscores Novavax’ commitment to creating a culture where our employees are a key part of innovative solutions, cutting-edge technology and shared success.”

The Washington Post publishes the complete list of Top Workplaces on June 21st. For more information about the Top Workplaces lists, please visit www.topworkplaces.com.

About Novavax

Novavax, Inc. (Nasdaq: NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the Company's website, novavax.com.

Contact:

Novavax, Inc.

Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer

Andrea N. Flynn, Ph.D.
Senior Manager, Investor Relations

[email protected]
240-268-2000

Russo Partners, LLC

David Schull
Todd Davenport, Ph.D.

[email protected]
[email protected]
212-845-4271  

You May Also Be Interested In

• Kadima Neuropsychiatry Institute Files Suit Against NRx Pharmaceuticals (NASDAQ: NRXP), Alleging Breach of Contract and Misrepresentation in Connection with Acquisition
• CALIFORNIA SCIENCE CENTER TO OPEN THE SAMUEL OSCHIN AIR AND SPACE CENTER ON NOVEMBER 13, 2026
• Asana Achieves FedRAMP® Moderate Authorization for Asana Gov